

Microbiology of Healthcare-Associated Infections

William A. Rutala, Ph.D., M.P.H.

Director, Statewide Program for Infection Control and Epidemiology
and Professor of Medicine, University of North Carolina at
Chapel Hill, NC, USA

Former Director, Hospital Epidemiology, Occupational Health and
Safety, UNC Hospitals, Chapel Hill, NC (38 years)

2025

1

Goals

- Microorganisms causing healthcare-associated infections
- Microbiological tools that can be used to “fingerprint” microorganisms

2

Properties of Microorganisms

	Size	Growth on Non-Living Media	DNA and RNA	Sensitivity to Antibiotics
Mycotic Agents				
Yeasts	3-15 μm	+	+	+
Molds	2-20 μm	+	+	+
Bacteria	1-5 μm	+	+	+
Mycoplasma	0.1-0.25 μm	+	+	+
Rickettsiae	0.3-0.7 μm	-	+	+
Chlamydiae	0.1-1.5 μm	-	+	+
Viruses	20-300nm	-	-	-

3

Sources of Healthcare-Associated Pathogens

Weinstein RA. Am J Med 1991;91 (suppl 3B):179S

- Endogenous flora (SSI, UTI, CLABSI): 40-60%
- Exogenous: 20-40% (e.g., cross-infection via contaminated hands [staff, visitors])
- Other (environment): 20%?
 - Medical devices/inanimate objects
 - Contact with environmental surfaces (direct and indirect)

4

Nosocomial Infections

Chain of Infection


- Agent
- Mode of transmission
 - Contact (direct, indirect, droplet spread)
 - Airborne
 - Common-vehicle spread
- Host

5


Mechanisms of Transmission

- Airborne-true airborne phase in route of dissemination
- Contact-victim has contact with source
 - Direct: Person-to-person (physical contact)
 - Indirect: Person-to-object-to-person (contact with contaminated intermediate object)
 - Droplet: <3 feet (brief passage of infectious agent through the air)
- Common-vehicle: Food, water, medical devices (contaminated inanimate vehicles serves as vector of agent to multiple persons)
- Vector-borne


6




7



8



9



10

HAI PATHOGENS, NHSN, 2011-2014

Weiner LM, et al. ICHE 2016;37:1288-130

TABLE 4. Distribution and Rank Order of Pathogens Frequently Reported to the National Healthcare Safety Network (NHSN), by Type of Healthcare-Associated Infection (HAI), 2011-2014

Pathogen	Overall		CLABSI		CAUTI		VAP ^a		SSI	
	No. (%) of pathogens	Rank ^b	No. (%) of pathogens	Rank ^b	No. (%) of pathogens	Rank ^b	No. (%) of pathogens	Rank ^b	No. (%) of pathogens	Rank ^b
<i>Escherichia coli</i>	62,904 (15.4)	1	5,193 (5.4)	7	36,806 (23.9)	1	476 (5.4)	6	20,429 (13.7)	2
<i>Staphylococcus aureus</i>	48,302 (11.8)	2	12,706 (13.2)	2	2,515 (1.6)	14	2,179 (24.7)	1	30,902 (20.7)	1
<i>Klebsiella (pneumoniae/syntropha)</i>	31,498 (7.7)	3	8,062 (8.4)	4	15,471 (10.1)	4	898 (10.2)	3	7,067 (4.7)	6
<i>Coagulase-negative staphylococci^c</i>	31,361 (7.7)	4	15,794 (16.4)	1	3,696 (2.4)	13	72 (0.8)	13	11,799 (7.9)	3
<i>Enterococcus faecalis^d</i>	30,034 (7.4)	5	8,118 (8.4)	3	10,278 (7.0)	5	32 (0.4)	21	11,156 (7.5)	4
<i>Pseudomonas aeruginosa</i>	29,836 (7.3)	6	3,881 (4.0)	10	15,848 (10.3)	3	1,449 (16.5)	2	8,458 (5.7)	5
<i>Candida albicans^e</i>	27,231 (6.7)	7	5,761 (6.0)	6	17,926 (11.7)	2	193 (2.2)	10	3,351 (2.2)	12
<i>Enterobacter spp^f</i>	17,235 (4.2)	8	4,204 (4.4)	9	5,689 (3.7)	9	727 (8.3)	4	6,615 (4.4)	8
<i>Enterococcus faecium^d</i>	14,942 (3.7)	9	6,567 (6.8)	5	4,212 (2.7)	11	23 (0.3)	24	4,340 (2.8)	11
Other <i>Enterococcus spp^d</i>	14,696 (3.6)	10	1,974 (2.0)	14	6,291 (4.3)	7	19 (0.2)	27	6,410 (4.3)	9
<i>Proteus spp^g</i>	11,249 (2.8)	11	820 (0.8)	17	6,108 (4.0)	8	125 (1.4)	12	4,196 (2.8)	10
<i>Yeast NOS^h</i>	10,811 (2.6)	12	763 (0.8)	18	9,443 (6.3)	6	54 (0.6)	16	551 (0.4)	25
Other <i>Candida sppⁱ</i>	10,641 (2.6)	13	4,730 (4.9)	8	5,178 (3.4)	10	37 (0.4)	19	696 (0.5)	19
<i>Candida glabrata^j</i>	8,121 (2.0)	14	3,314 (3.4)	11	4,121 (2.7)	12	12 (0.1)	33	674 (0.5)	20
%MRSA by site: CLABSI, 50.7%; VAP, 42.4% (2012); SSI, 42.6% (2014); CAUTI, 5(2014) ^k	31,942 (12.7)		14,336 (14.8)		9,771 (6.4)		2,907 (35.3)		23,524 (17.1)	7
Total	408,152 (100)		96,532 (100)		153,805 (100)		8,805 (100)		149,009 (100)	

11


Relative Frequency of HA Pathogens, 1980-2008

Kang, Sickbert-Bennett, Brown, Weber, Rutala. AJIC, 2012


Table 1
Changes in relative frequency of health care-associated pathogens by time blocks from 1980 to 2008

Organism	Total (1980-2008)		Percent of each time block						Trend analysis	
	Rank	No. %	1980-1984	1985-1989	1990-1994	1995-1999	2000-2004	2005-2008	% Change	P-value
<i>Staphylococcus aureus</i>	1	5,483 15.4	11.8	11.2	16.0	18.2	17.3	15.5	5.3	<.0001
<i>Escherichia coli</i>	2	3,753 10.6	12.6	12.7	11.3	9.2	8.2	11.5	-3.1	<.0001
<i>Coagulase-negative staphylococci</i>	3	3,587 10.1	6.9	7.6	8.1	12.7	13.2	9.2	4.8	<.0001
<i>Candida</i> and other yeasts	4	3,494 9.8	7.7	10.4	11.0	10.3	11.1	8.1	3.0	.1890
<i>Enterococcus spp</i>	5	3,138 8.8	8.1	5.8	8.0	8.8	10.2	10.7	3.8	<.0001
<i>Pseudomonas aeruginosa</i>	6	2,954 8.3	9.5	9.5	9.7	8.6	6.7	7.1	-3.1	<.0001
<i>Klebsiella spp</i>	7	2,186 6.2	7.3	7.7	5.9	6.3	4.9	5.7	-2.4	<.0001
<i>Enterobacter spp</i>	8	2,097 5.9	7.2	8.2	6.3	4.8	4.7	5.7	-2.7	<.0001
Other streptococci	9	1,252 3.5	5.0	4.1	2.8	3.6	3.1	2.9	-1.8	<.0001
<i>Clostridium difficile</i> and other anaerobes	10	1,044 2.9	3.3	3.2	2.9	1.5	1.9	5.5	0.8	.0025
<i>Proteus spp</i>	11	946 2.7	5.4	3.9	2.1	1.6	1.9	2.1	-1.8	<.0001
<i>Serratia spp</i>	12	802 2.3	3.8	2.5	2.1	1.8	2.1	1.7	0.8	<.0001
<i>Acinetobacter spp</i>	13	593 1.7	1.2	1.4	2.2	1.4	2.1	1.6	-1.5	.0163
<i>Haemophilus spp</i>	14	494 1.4	1.6	2.5	2.2	1.1	0.9	0.8	-2.0	<.0001
<i>Bacteroides spp</i>	15	349 1.0	2.6	1.6	1.0	0.3	0.4	0.7	-0.8	<.0001
<i>Citrobacter spp</i>	16	325 0.9	1.1	1.1	0.9	0.8	0.9	0.8	0.5	.0488
<i>Group B streptococci</i>	17	324 0.9	1.4	1.3	1.1	0.5	0.6	0.9	-0.3	<.0001
Other	18	2,689 7.6	3.5	5.2	6.2	8.5	10.0	9.5	6.7	<.0001
Total (n)		35,510	5,217	4,336	4,904	6,964	7,999	6,090		


12




13




14




15




16




17



18



19




20

Bundled Approach to Reduce *C. difficile*

(two-step GDH-glutamate dehydrogenase/toxin and NAAT-nucleic acid amplification) (2015-2017)
Schultz et al. J Clin Microbiol 2018;56:1-10

- Diagnostic Stewardship
 - Only unforned liquid stool tested
 - No testing from patients with positive *C. difficile* test in previous 14 days
 - Testing restricted for patients with negative *C. difficile* in previous 7 days
 - Discouraged testing patients who received laxatives and/or stool softeners in previous 48 hours
- Enhanced Isolation-to 30 days after cessation of antibiotics
- Environmental C/D-standardized plan; UV
- Antimicrobial stewardship-reduce 3rd/4th generation cephalosporins and fluoroquinolones
- Hand Hygiene-clean in, clean out; immediate feedback

21



22

Pathogens of Epidemiologic Importance

- Carbapenem resistant**
 - 3 of 28 (11%) *Enterobacter cloacae*
 - 2 of 131 (1.5%) *Escherichia coli*
 - 1 of 80 (1.3%) *Klebsiella pneumoniae*
- Multi-drug resistant**
 - 5 of 28 (18%) *Enterobacter cloacae*
 - 16 of 131 (12%) *Escherichia coli*
 - 1 of 9 (11%) *Acinetobacter sp.*
 - 8 of 73 (11%) *Pseudomonas aeruginosa*
 - 1 of 10 (10%) *Klebsiella aerogenes*
 - 4 of 80 (5%) *Klebsiella pneumoniae*
- Other drug resistant**
 - 15 of 73 (20.5%) *Enterococcus* were vancomycin resistant
 - 58 of 116 (50%) *Staphylococcus aureus* were oxacillin resistant

These percentages are relatively similar to percentages for CRE and MDR reported in past few years

2024

23

Other Pathogens of Epidemiologic Importance

- 129 *Clostridioides difficile*
- 54 Rhinovirus/enterovirus
- 51 SARS-CoV-2
- 14 Parainfluenza viruses
- 10 Respiratory Syncytial virus
- 9 endemic coronaviruses
- 9 Adenovirus
- 8 Group B *Streptococcus*
- 4 Influenza A
- 4 *Haemophilus influenzae*
- 3 *Aspergillus sp.*
- 3 Metapneumovirus
- 1 *Fusarium*
- 2 *Mycobacterium abscessus*
- 1 *Mycobacterium mucogenicum*
- 1 *Mycobacterium chelonae*

2024

24

Pathogens of Epidemiologic Importance

- **Carbapenem resistant**
 - 4 of 65 (6%) *Pseudomonas aeruginosa*
 - 1 of 36 (3%) *Enterobacter cloacae*
 - 1 of 12 (8%) *Klebsiella oxytoca*
- **Multi-drug resistant**
 - 19 of 65 (29%) *Pseudomonas aeruginosa*
 - 10 of 158 (6%) *Escherichia coli*
 - 7 of 36 (19%) *Enterobacter cloacae*
 - 7 of 67 (10%) *Klebsiella pneumoniae*
 - 3 of 30 (10%) *Serratia marcescens*
- **Other drug resistant**
 - 14 of 83 (17%) *Enterococcus* were vancomycin resistant
 - 61 of 146 (42%) *Staphylococcus aureus* were oxacillin resistant

These percentages are similar to percentages for CRE, MDR and other drug resistant reported in past few years

2022

25

Other Pathogens of Epidemiologic Importance

- 141 *Clostridioides difficile*
- 75 SARS-CoV-2
- 35 Rhinovirus/enterovirus
- 8 Influenza A
- 6 Respiratory Syncytial Virus
- 6 *Mycobacterium abscessus*
- 5 endemic coronaviruses
- 3 Adenovirus
- 3 Group B *Streptococcus*
- 2 *Aspergillus* sp.
- 2 Metapneumovirus
- 2 Parainfluenza viruses
- 1 *Fusarium*
- 1 *Haemophilus influenzae*
- 1 *Mycobacterium immunogenum*
- 1 *Mycobacterium fortuitum*
- 1 Mold
- 1 *Neisseria meningitidis*

In 2021, there were 17 HAI with SARS-CoV-2, however, in 2022 there were 75. Overall, there were more HAI with respiratory viruses (e.g. rhinovirus/enterovirus, influenza A) likely due to the increased prevalence of these pathogens in the community compared to 2020/2021, when COVID mitigation strategies were more widely/consistently implemented.

2022

26

Conclusions and Recommendations

UNC Medical Center, 2024

- HAI pathogens recovered at UNC Hospitals are similar in spectrum to nationally reported data.
- The proportion of vancomycin-resistance among *Enterococcus* decreased slightly and the VRE HAI rate remained relatively stable in 2024 compared to 2023.
- The proportion of oxacillin-resistance among *Staphylococcus aureus* and the MRSA HAI rate increased in 2023 compared to 2023.
- HAI rates of MDR Gram negative bacteria and CRE decreased in 2024 and remain low.

27

Goals


- Microorganisms causing healthcare-associated infections
- Microbiological tools that can be used to “fingerprint” microorganisms

28


Microbiological Tools That Can Aid an Infection Preventionists

- Biotyping: use of biochemical reactions to differentiate bacteria
- Antibigrams: antimicrobial susceptibility
- Phage Typing: certain bacteria under bacterial phage attachment and subsequent lysis
- Serotyping: whole microorganisms or its components can be used as antigenic sources for a variety of serologic schemes
- Molecular Typing: microbial DNA fingerprinting (e.g., PFGE, whole genome sequence analysis)
- MALDI-TOF mass spectrometry for organism ID (new tools bring efficiencies to ID process; peptide map used to search sequence database)


29




30



31



32



33




34

Outbreak of *P. cepacia* Bacteremia Associated with IABP


Rutala et al. J Thoracic Cardio Surg 1988

- Cluster: Symptomatic *P. cepacia* bacteremia in 2 patients in CTICU within 3 days after insertion of IABP
- Evaluation: Both patients needed IABP for circulatory support
- Results: IABP water reservoir contained more than 10^5 /ml *P. cepacia*. Also recovered from purge button, on-off switch, hands of HCP who manipulated the water reservoir
- Agarose gel electrophoresis of *P. cepacia* revealed 3 identical plasmids
- Transmission from workers hands to patients occurred by inoculation of intravascular lines during management


35



36



37



38

Faucet Aerators: Source of Patient Colonization with *S. maltophilia*

Weber, Rutala et al. AJIC

- Cluster of patients in SICU C/I with *S. maltophilia*
- Environmental isolates obtained from water sources
- Two isolates of *S. maltophilia* were identical to strains isolated from the faucet aerators in sinks in the patients' rooms (lanes 3,4 and lanes 6,7-patient and sink aerator)
- Believed low-level contamination of water led to contamination of faucet aerators with amplification on the aerator.
- If clusters of C/I linked to aerators, consider given to routine disinfection or removal

39



40

Whole Genome Sequencing

Heater Cooler Units

- Current manufacturers
 - LivaNova (Sorin)
 - Maquet
 - Cardioquip
 - Terumo
 - Cincinnati-Sub-Zero



41

SOURCE OF *M. CHIMAERA* OUTBREAK

- Point-source contamination of 3T HCU suggested by 2 studies
 - Europe: *M. chimaera* isolates from 5 patients, 3T HCU from 3 different countries and from new 3T HCU and environment at manufacturer facility – identical by sequencing (typing unpublished – preliminary)
 - US: *M. chimaera* isolates from 11 patients and 5 3T HCU from PA and Iowa were the same by whole genome sequencing
- Manufacturing facility added disinfection and active drying procedures to production line in Sept 2014 due to *M. chimaera* contamination

Contamination during production of heater-cooler units by *Mycobacterium chimaera* potential cause for invasive cardiovascular infections: results of an outbreak investigation in Germany, April 2015 to February 2016

Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in Cardiac Surgery – United States

Haller S, et al. Euro Surveill 2016;21(17), April 28 Perkins KM, et al. MMWR 2016;65:1117

42

THANK YOU!
www.disinfectionandsterilization.org

